Vyleesi (Bremelanotide) HSDD 指南 2026
完整指南与证据 (2026)
Vyleesi (Bremelanotide) 完整指南,这是一种经 FDA 批准用于治疗女性性欲低下障碍 (HSDD) 的多肽药物。
核心生物机制
黑素皮质素受体(MC1R 和 MC4R)的非选择性激动剂
MC4R 结合直接调节性反应和唤起
作用于欲望阶段——恢复性欲,而不仅仅是生理机制
刺激黑素皮质素通路导致下游多巴胺释放
多巴胺是负责期待、奖励和欲望的主要神经递质
效果在注射后 45-60 分钟内逐渐显现
给药方案
皮下注射(SubQ)于腹部或大腿。
在预期活动前至少 45 分钟使用。
24 小时内不得超过一剂,每月最多 8 剂。
注意:约 40% 的患者会出现严重恶心。通常需要配合止吐药或缓慢滴定。切勿超过剂量限制——这会导致血压剧烈飙升。
副作用与安全性
Common Effects
Nausea (40% of patients — most common). Facial flushing and warmth. Headache. Injection site reactions
Important Warnings
Focal hyperpigmentation if used more than 8x/month. Blood pressure elevation at higher doses. Not for use in men (off-label PT-141 is different). Skin darkening of gums, face, or breasts possible
关键方案常见问题
Why does Vyleesi cause such bad nausea?
Because it activates melanocortin receptors everywhere, it triggers nausea centers in the brain. For many, nausea fades after a few uses, but for some it requires discontinuation.
Does Vyleesi work for men?
While exclusively FDA-approved for premenopausal women, the generic peptide (Bremelanotide/PT-141) is widely used in men for inducing spontaneous erections by bypassing nitric-oxide pathways.
Will it darken my skin?
Yes, focal hyperpigmentation was observed in trials if used more than 8 times a month, due to MC1R (tanning receptor) activation.
指南常见问题
Vyleesi (Bremelanotide) 完整指南,这是一种经 FDA 批准用于治疗女性性欲低下障碍 (HSDD) 的多肽药物。
可以。Shotlee 支持追踪 Vyleesi 的剂量、副作用和健康指标。该应用可免费使用。
参考文献
- [1]Clinical TrialKingsberg SA et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder (RECONNECT). Obstet Gynecol. 2019;134(5):899-908.
- [2]ReviewClayton AH et al. Bremelanotide for female sexual dysfunctions in premenopausal women. Exp Opin Investig Drugs. 2018;27(12):975-985.
- [3]FDAAMAG Pharmaceuticals. Vyleesi (bremelanotide) Prescribing Information. U.S. FDA.